Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Theravance Bio Ord (NQ: TBPH )

9.640 +0.170 (+1.80%)
Streaming Delayed Price Updated: 9:35 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Theravance Bio Ord

< Previous 1 2 3 4 5 6 Next >
Earnings Scheduled For February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. 
Via Benzinga
Earnings Preview: Theravance Biopharma
Via Benzinga
Target To Rally 29%? Plus This Analyst Predicts $245 For IQVIA Holdings
Piper Sandler boosted the price target on Target Corporation (NYSE: TGT) from $190 to $200. Target shares fell 13.1% to close at $155.47 on Wednesday. 
Via Benzinga
Earnings Scheduled For November 7, 2022
Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million. 
Via Benzinga
A Preview Of Theravance Biopharma's Earnings
Theravance Biopharma (NASDAQ:TBPH) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Here's Why Theravance Biopharma Shares Are Moving
Theravance Biopharma Inc (NASDAQ: TBPH) shares are trading higher by 2.78% to $10.35 Monday afternoon after the company authorized a $250 million capital return program. What Else? 
Via Benzinga
Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings
Via Benzinga
Looking Into Theravance Biopharma's Return On Capital Employed
According to data from Benzinga Pro, during Q2, Theravance Biopharma's (NASDAQ:TBPH) reported sales totaled $11.05 million. Despite a 68.43% increase in earnings, the company posted a loss of $8.19... 
Via Benzinga
Theravance Biopharma's Earnings: A Preview
Theravance Biopharma (NASDAQ:TBPH) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Why Is Conagra Brands Dropping By More Than 8%? 43 Stocks Moving In Thursday's Mid-Day Session
Gainers Shineco, Inc. (NASDAQ: SISI) shares climbed 24.5% to $1.2201 on heavy volume. 
Via Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're diving into all the latest stock market news with a breakdown of the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
Why Is Ericsson Down By 9%? 22 Stocks Moving In Thursday's Pre-Market Session
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 22.1% to $0.2050 in pre-market trading. Allena Pharmaceuticals disclosed a new meeting date and new record date for special meeting to approve... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
Via Benzinga
Theravance Biopharma's Earnings Outlook
Theravance Biopharma (NASDAQ:TBPH) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Theravance Biopharma's Ampreloxetine Shows Benefit In Atrophy Patients, But Not In Parkinson's
Theravance Biopharma Inc (NASDAQ: TBPH)  
Via Benzinga
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Why Theravance Biopharma Stock Is Trading Lower After Hours
Theravance Biopharma Inc (NASDAQ: TBPH) shares are trading lower in Monday's after-hours session after the company announced the results from Study 0170 showed the... 
Via Benzinga
World Markets News For Friday
Buoyant global markets are closing the week and one good performer, Vir Biotech, today gained an impressive 6.09%. 
Via Talk Markets
Red Ink
There is little joy in stocks today as even companies reporting good results are being hit by fear of Ukraine sanctions.tbph 
Via Talk Markets
Recap: Theravance Biopharma Q4 Earnings
Theravance Biopharma (NASDAQ:TBPH) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers SCYNEXIS (NASDAQ:SCYX) shares inc... 
Via Benzinga
Give peace a chance
Israeli fabless semiconductor maker Tower was bought by Intel for $5.4 bn today. 
Via Talk Markets
Nuclear Winter
Mexico is raising interest rates to 6%, from 5.5%. 
Via Talk Markets
Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)... 
Via Benzinga
The Last Day In January
The market is suspicious of the moves up to right matters. 
Via Talk Markets
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.